Induced from Eric Ma’s hallway conversation at the KENX AI in GxP East 2026 conference (2026-09-16-1237-gxp-compliance-data-science-careers-discussion), 2026-09-16.
The framing that made the density make sense
GxP exists to build institutional trust on behalf of patients. Once said, the documentation density of GxP digital platforms stops looking like bureaucratic drag: every signature, audit trail, and SOP exists so that a stranger can trust a medicine they will never see being made. The promise to patients that medicines are made exactly as documented, and backed by evidence, is the bedrock the enforcement system defends. That promise is also the risk-sizing anchor in Regulators audit against principles, so size quality rigor to risk.
What broken trust costs
The enforcement stories are the negative proof: employees fired for backdating by a single day, investigators collecting trash cans to find sticky-note calculations from technicians forbidden writing instruments, a consent decree that drove an Indian generic manufacturer to closure, and its US customer hiring lawyers and roughly fifty private consultants to re-review twenty years of packages. Trust, once broken, is bought back at multiples. Inspections test the promise by watching the process, which is why Regulatory inspections verify execution against SOPs, not the existence of documents, and why the operator’s only safe move is Never guess in an inspection; say you will double check.